6 completed. 4 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Bond Avillion 2 Development LP: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma BDA MDI, AS MDI - Asthma | Phase 3 | Completed | Bond Avillion 2 Development LP | 2516 | 2022-09-02 | 2025-08-03 |
| To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years. BDA MDI (PT027) 160/180 μg, Pulmicort Respules 0.5 MG/ML Inhalation Suspension - Asthma | Phase 1 | Completed | Bond Avillion 2 Development LP | 12 | 2021-05-06 | 2022-05-11 |
| A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Placebo metered-dose inhaler - Exercise Induced Bronchospasm | Phase 3 | Completed | Bond Avillion 2 Development LP | 60 | 2020-01-15 | 2022-01-13 |
| A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg - Asthma | Phase 3 | Completed | Bond Avillion 2 Development LP | 1001 | 2019-03-20 | 2023-04-13 |
| A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg - Asthma | Phase 3 | Completed | Bond Avillion 2 Development LP | 3132 | 2018-12-13 | 2022-09-28 |
| A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis M1095 (Sonelokimab), Placebo, Secukinumab - Psoriasis | Phase 2 | Completed | Bond Avillion 2 Development LP | 313 | 2018-07-31 | 2021-08-03 |
Asthma (4) · Asthma, Exercise-Induced (1) · Psoriasis (1)
Budesonide (4) · secukinumab (1) · sonelokimab (1)
United States (6) · Czechia (3) · Germany (3) · Argentina (2) · Canada (2) · Serbia (2) · Slovakia (2) · Ukraine (2) · Bulgaria (1) · Hungary (1) · Poland (1) · South Africa (1) · Spain (1) · United Kingdom (1)
Frank Albers, MD, PhD (4) · Craig LaForce, MD (1) · Dr. Kim Papp (1)
PMID 33894834, PMID 34699967, PMID 35569035, PMID 36161875, PMID 37003355, PMID 40388330, PMID 40664332
2018 (1)